Cargando…
Clinical Proof-of-Concept Study With MSDC-0160, a Prototype mTOT-Modulating Insulin Sensitizer
It may be possible to achieve insulin sensitivity through the recently identified mitochondrial target of thiazolidinediones (mTOT), thereby avoiding peroxisome proliferator–activated receptor-γ (PPAR-γ)-dependent side effects. In this phase IIb clinical trial, 258 patients with type 2 diabetes comp...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3604641/ https://www.ncbi.nlm.nih.gov/pubmed/23462886 http://dx.doi.org/10.1038/clpt.2013.10 |
_version_ | 1782263776049889280 |
---|---|
author | Colca, J R VanderLugt, J T Adams, W J Shashlo, A McDonald, W G Liang, J Zhou, R Orloff, D G |
author_facet | Colca, J R VanderLugt, J T Adams, W J Shashlo, A McDonald, W G Liang, J Zhou, R Orloff, D G |
author_sort | Colca, J R |
collection | PubMed |
description | It may be possible to achieve insulin sensitivity through the recently identified mitochondrial target of thiazolidinediones (mTOT), thereby avoiding peroxisome proliferator–activated receptor-γ (PPAR-γ)-dependent side effects. In this phase IIb clinical trial, 258 patients with type 2 diabetes completed a 12-week protocol with 50, 100, or 150 mg of MSDC-0160 (an mTOT modulator), 45 mg pioglitazone HCl (a PPAR-γ agonist), or a placebo. The two active treatments lowered fasting glucose levels to the same extent. The decreases in glycated hemoglobin (HbA(1c)) observed with the two higher doses of MSDC-0160 were not different from those associated with pioglitazone. By contrast, fluid retention as evidenced by reduction in hematocrit, red blood cells, and total hemoglobin was 50% less in the MSDC-0160–treated groups. There was also a smaller increase in high-molecular-weight (HMW) adiponectin with MSDC-0160 than with pioglitazone (P < 0.0001), suggesting that MSDC-0160 produces less expansion of white adipose tissue. Thus, mTOT modulators may have glucose-lowering effects similar to those of pioglitazone but without the adverse effects associated with PPAR-γ agonists. |
format | Online Article Text |
id | pubmed-3604641 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-36046412013-04-01 Clinical Proof-of-Concept Study With MSDC-0160, a Prototype mTOT-Modulating Insulin Sensitizer Colca, J R VanderLugt, J T Adams, W J Shashlo, A McDonald, W G Liang, J Zhou, R Orloff, D G Clin Pharmacol Ther Articles It may be possible to achieve insulin sensitivity through the recently identified mitochondrial target of thiazolidinediones (mTOT), thereby avoiding peroxisome proliferator–activated receptor-γ (PPAR-γ)-dependent side effects. In this phase IIb clinical trial, 258 patients with type 2 diabetes completed a 12-week protocol with 50, 100, or 150 mg of MSDC-0160 (an mTOT modulator), 45 mg pioglitazone HCl (a PPAR-γ agonist), or a placebo. The two active treatments lowered fasting glucose levels to the same extent. The decreases in glycated hemoglobin (HbA(1c)) observed with the two higher doses of MSDC-0160 were not different from those associated with pioglitazone. By contrast, fluid retention as evidenced by reduction in hematocrit, red blood cells, and total hemoglobin was 50% less in the MSDC-0160–treated groups. There was also a smaller increase in high-molecular-weight (HMW) adiponectin with MSDC-0160 than with pioglitazone (P < 0.0001), suggesting that MSDC-0160 produces less expansion of white adipose tissue. Thus, mTOT modulators may have glucose-lowering effects similar to those of pioglitazone but without the adverse effects associated with PPAR-γ agonists. Nature Publishing Group 2013-04 2013-03-06 /pmc/articles/PMC3604641/ /pubmed/23462886 http://dx.doi.org/10.1038/clpt.2013.10 Text en Copyright © 2013 American Society of Clinical Pharmacology and Therapeutics http://creativecommons.org/licenses/by-nc-nd/3.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-No Derivative Works 3.0 License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ |
spellingShingle | Articles Colca, J R VanderLugt, J T Adams, W J Shashlo, A McDonald, W G Liang, J Zhou, R Orloff, D G Clinical Proof-of-Concept Study With MSDC-0160, a Prototype mTOT-Modulating Insulin Sensitizer |
title | Clinical Proof-of-Concept Study With MSDC-0160, a Prototype mTOT-Modulating Insulin Sensitizer |
title_full | Clinical Proof-of-Concept Study With MSDC-0160, a Prototype mTOT-Modulating Insulin Sensitizer |
title_fullStr | Clinical Proof-of-Concept Study With MSDC-0160, a Prototype mTOT-Modulating Insulin Sensitizer |
title_full_unstemmed | Clinical Proof-of-Concept Study With MSDC-0160, a Prototype mTOT-Modulating Insulin Sensitizer |
title_short | Clinical Proof-of-Concept Study With MSDC-0160, a Prototype mTOT-Modulating Insulin Sensitizer |
title_sort | clinical proof-of-concept study with msdc-0160, a prototype mtot-modulating insulin sensitizer |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3604641/ https://www.ncbi.nlm.nih.gov/pubmed/23462886 http://dx.doi.org/10.1038/clpt.2013.10 |
work_keys_str_mv | AT colcajr clinicalproofofconceptstudywithmsdc0160aprototypemtotmodulatinginsulinsensitizer AT vanderlugtjt clinicalproofofconceptstudywithmsdc0160aprototypemtotmodulatinginsulinsensitizer AT adamswj clinicalproofofconceptstudywithmsdc0160aprototypemtotmodulatinginsulinsensitizer AT shashloa clinicalproofofconceptstudywithmsdc0160aprototypemtotmodulatinginsulinsensitizer AT mcdonaldwg clinicalproofofconceptstudywithmsdc0160aprototypemtotmodulatinginsulinsensitizer AT liangj clinicalproofofconceptstudywithmsdc0160aprototypemtotmodulatinginsulinsensitizer AT zhour clinicalproofofconceptstudywithmsdc0160aprototypemtotmodulatinginsulinsensitizer AT orloffdg clinicalproofofconceptstudywithmsdc0160aprototypemtotmodulatinginsulinsensitizer |